JP2014201591A - 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 - Google Patents

医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 Download PDF

Info

Publication number
JP2014201591A
JP2014201591A JP2014077939A JP2014077939A JP2014201591A JP 2014201591 A JP2014201591 A JP 2014201591A JP 2014077939 A JP2014077939 A JP 2014077939A JP 2014077939 A JP2014077939 A JP 2014077939A JP 2014201591 A JP2014201591 A JP 2014201591A
Authority
JP
Japan
Prior art keywords
exposure
ionizing radiation
genistein
image processing
medical image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014077939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014201591A5 (enExample
Inventor
マイケル・ディー・ケイター
D Kaytor Michael
ジョン・エル・ゼンク
L Zenk John
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humanetics Corp
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Publication of JP2014201591A publication Critical patent/JP2014201591A/ja
Publication of JP2014201591A5 publication Critical patent/JP2014201591A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014077939A 2013-04-04 2014-04-04 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 Pending JP2014201591A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/856,909 2013-04-04
US13/856,909 US9623003B1 (en) 2013-04-04 2013-04-04 Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein

Publications (2)

Publication Number Publication Date
JP2014201591A true JP2014201591A (ja) 2014-10-27
JP2014201591A5 JP2014201591A5 (enExample) 2017-05-25

Family

ID=50439162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014077939A Pending JP2014201591A (ja) 2013-04-04 2014-04-04 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法

Country Status (3)

Country Link
US (3) US9623003B1 (enExample)
EP (1) EP2786751A1 (enExample)
JP (1) JP2014201591A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
US9623004B2 (en) 2013-08-02 2017-04-18 Humanetics Corporation Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy
US20150126597A1 (en) * 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
CA3207497A1 (en) * 2021-01-11 2022-07-14 Humanetics Corporation Genistein treatment of inflammatory and immunological disorders
CN114948869A (zh) * 2022-05-26 2022-08-30 中国药科大学 一种染料木素纳米混悬液的制备方法及该方法制备的染料木素纳米混悬液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068140A1 (en) * 2010-11-15 2012-05-24 Humanetics Corporation Nanoparticle isoflavone compositions & methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523087A (en) 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
US5824702A (en) 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
JP3502374B2 (ja) 1999-08-27 2004-03-02 チェイル ジェダン コーポレーション プエラリア・ミリフィカ、ブテア・スペルバおよび／またはムクナ・コレッチ由来の抽出物並びにその抽出方法
ES2288169T3 (es) 2000-06-14 2008-01-01 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Isoflavonas contra la mortalidad inducida por radiacion.
CA2416796A1 (en) 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
GB0302882D0 (en) 2003-02-07 2003-03-12 Univ Cardiff Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
WO2006091187A1 (en) 2005-02-22 2006-08-31 Landauer Michael R Isoflavonoids for preventing radiation- and chemotherapy- induced weight loss
ES2369928T3 (es) 2005-06-29 2011-12-09 Dsm Ip Assets B.V. Nanopartículas de isoflavonas y su utilización.
CN102933258A (zh) 2010-03-01 2013-02-13 因特奥普医药公司 与含氧量低的细胞敏化剂联用的放疗
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068140A1 (en) * 2010-11-15 2012-05-24 Humanetics Corporation Nanoparticle isoflavone compositions & methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.F.WILLIAMSON, ET AL: "Radiation Biology, Safety and Protection for Today's Dental Team", DENTALCARE.COM, JPN7018000257, 2012, pages 1 - 29 *

Also Published As

Publication number Publication date
US9623003B1 (en) 2017-04-18
US10220018B2 (en) 2019-03-05
EP2786751A1 (en) 2014-10-08
US20180256535A1 (en) 2018-09-13
US20170172976A1 (en) 2017-06-22
US9993455B2 (en) 2018-06-12

Similar Documents

Publication Publication Date Title
US10220018B2 (en) Method of mitigating long and short term detrimental effects of exposure to low dose ionizing radiation by administration of genistein
Gersten et al. Ototoxicity and platinum uptake following cyclic administration of platinum-based chemotherapeutic agents
Yamazaki et al. Effects of (−)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
WO2016118014A2 (en) Anti-senescence compounds and uses thereof
CN103462896A (zh) 诱导癌细胞凋亡的方法和应用
US20150126597A1 (en) Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
US20250262225A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
WO2020015732A1 (zh) 亚砜类化合物在预防放射性神经系统疾病中的用途
KR102159427B1 (ko) 지방 감소를 위한 미용적 방법 및 치료적 용도
Lu et al. Hypothermic properties of dexmedetomidine provide neuroprotection in rats following cerebral ischemia-reperfusion injury
TW201341352A (zh) 用於治療癌症轉移之方法和組合物
US20180193363A1 (en) Methods and compositions for protection of cells and tissues from computed tomography radiation
TWI469784B (zh) 可治療癌症之藥學組合物
DiMario Jr Tuberous sclerosis complex
JP2014231518A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
CN114432455A (zh) 一种慢性疼痛-抑郁共病治疗药物的制备及其应用
KR20180041742A (ko) 방사선 손상에 대한 보호를 위한 세코이솔라리시레시놀 디글루코사이드(SDGs) 및 관련 화합물의 용도
WO2024006901A1 (en) Uses of bipolar trans carotenoids in the treatment of cancer
CA3235075A1 (en) Methods of treating head and neck cancers with hemp extract
US20200268779A1 (en) USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION
Dorszewska et al. P2. 083 Level of oxidative DNA damage and expression of apoptotic proteins in patients with Parkinson's disease treatment with L-dopa
HK40029827A (en) Agent for treatment of nervous system disease
HK1185280A (en) Methods and compositions for treating cancer metastasis
Leideck et al. P2. 085 Piribedil stimulates dopaminergic neurons via dopamine receptor activation and PI3-kinase signalling and protects against MPP+ toxicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731